Celldex Therapeutics (CLDX) Discontinues Study of Brain Cancer Vaccine, Shares Crater

Shares of Celldex Therapeutics Inc. (CLDX) were trading down -4.28 or -52.26 percent to $3.91 per share in Monday's premarket after the company announced the discontinuation of a late stage study of its brain cancer vaccine. Celldex Therapeutics stock closed at $8.19, down -0.06 or -0.73 percent in Friday's regular trading session. Hampton, New Jersey ... READ MORE Read the rest of Celldex Therapeutics (CLDX) Discontinues Study of Brain Cancer Vaccine, Shares Crater at InvestorGuide.com .